Silymarin does not modify virus activity or ALT levels in
Accepted release date: 1-Feb-2008 E-mail Article Contact:
Amy Molnar amolnar wiley.com Wiley-Blackwell Silymarin does not affect virus labor or ALT levels in In a survey of patients with chronic hepatitis C who participated in a National Institute of Diabetes and Digestive and Kidney Diseases-sponsored long-term care of evaluation championing patients who had failed to respond previously to antiviral therapy, sorrounding 40% acknowledged to interviewers at the time of enrollment that they were currently using or had in the recent recent used herbal issue for health purposes.
Among those who were or had used alternative therapies, silymarin (milk thistle) was the product of election either on its own or together with other herbal products, representing 72% of all the herbals taken.
These findings are in the February issue of Hepatology, a magazine published next to Wiley & Sons on in one's behalf for of the American Association for the Announce of Liver Diseases (AASLD).
The article was also available online at Wiley Interscience ( http:
Still, in comparing users with non-users, while no difference was establish for blood ALT or HCV levels between the two groups, the herbal users did announcement somewhat fewer symptoms and a better standard of life.
The current recommended treatment of behaviour towards for patients with HCV infection is mixture therapy with pegylated interferon and ribavirin.
However, it leads to a sustained virological retort in one a third to a half of all patients with the predominant form of the infection in the U.S., 1, and it can cause unpleasant and sometimes serious margins effects.
The impetus for interviewing enrollees in the trial was to determine the extent of handle of alternative therapies in this committed group, since the popularity of herbal output has increased in the U.S., HCV patients choosing to supplement, or even replace, the standard treatment with herbals.
Silymarin (milk thistle extract) has been the most common option for mankind with liver disease. For the present survey, researchers interviewed all HALT-C sharer on past and current use of all formula and non-prescription drugs, including herbal medications, dietary supplements and other botanical products.
Of 1145 study participants, 56 percent said that they had never hand-me-down herbal products, while 23 percent were using them currently, some 60 antithetic varieties. Silymarin was by far the most common. Usage was higher among men, in the midst non-Hispanic whites, and among the more highly educated.
Interestingly, the researchers also found geographic disparities in silymarin usage. It was most popular in Colorado, Michigan and Southern California and least popular in Maryland and Massachusetts.
In comparing the clinical data of silymarin users and non-users, the researchers found that "the levels of HCV RNA were not significantly disparate between silymarin users and non-users," indicating no backwash on virus activity. Similarly, the product did not alter serum ALT levels, indicating no effect on hepatic inflammation.
However, after adjusting for covariates, the data showed that silymarin users reported less fatigue, nausea, liver pain, anorexia, muscle and joint despondency and better general health than non-users.
The better scores in a meager figure of symptoms middle silymarin users compared to non-users are inadequate to support the value of this alternative therapy, the authors conclude. Compelling information can come only if a scientifically valid study is performed.
Currently in progress, therefore, is a properly designed prospective, randomized, controlled trial in which a fully characterized, purified and standardized silymarin formulation is being evaluated," they report.
From http://eurekalert.org/pub_releases/2008-02/w-sdn020108.php